1. Scrip
  2. >>Business

New appointment at Xention

 
• By Zoë Dann

Dr Patrick Round has been named chief medical officer and head of development at Xention, a UK biopharmaceutical company discovering and developing ion channel-modulating drugs. Dr Round has worked as senior vice-president at Cambridge Antibody Technology, director of development at Celltech R&D, director of clinical development at Glaxo Wellcome, clinical project manager at Novo Nordisk Pharmaceuticals and chief medical officer at Phoqus Pharmaceuticals.

Dr Patrick Round has been named chief medical officer and head of development at Xention, a UK biopharmaceutical company discovering and developing ion channel-modulating drugs. Dr Round has worked as senior vice-president at Cambridge Antibody Technology, director of development at Celltech R&D, director of clinical development at Glaxo Wellcome, clinical project manager at Novo Nordisk Pharmaceuticals and chief medical officer at Phoqus Pharmaceuticals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.